

## Dechra Pharmaceuticals PLC US Appointment

Dechra Pharmaceuticals PLC, a leading manufacturer, distributor and marketer of veterinary pharmaceuticals today announces the appointment of Mike Eldred to head up the Group's American marketing drive.

Mike joins Dechra as President of the Group's newly established US operations, Dechra Veterinary Products, which is centrally located within the US in Kansas City, Missouri. He has over 12 years professional experience in the animal health sector, having held senior positions at a number of leading US veterinary pharmaceutical organizations.

Mike developed his career with Fort Dodge Animal Health, GARMIN International and Sanofi Animal Health in Kansas before joining Virbac Corporation a manufacturer of veterinary pharmaceuticals, oral hygiene and dermatological products based in Fort Worth, Texas in 2000. Initially, he was Director of Supply Chain and Customer Service, where he was responsible for all supply chain activities including demand management, planning, purchasing, customer service and distribution. In 2001, Mike was promoted to Director of Business Development, Contract Manufacturing and Corporate Business. In this role he directed and coordinated Virbac's acquisition, divestiture, licensing agreements and business alliances.

Mike received an MBA from the University of Missouri in Kansas City in 1999 and a BA Business degree in 1992 at the University of Northern Iowa.

Commenting on the appointment, Ian Page, Chief Executive, Dechra Pharmaceuticals PLC said:

*"We are delighted to welcome Mike to the Group as President of our US operations. With the American market being some ten times larger than that of the UK, and having an existing high level of awareness of Cushing's Disease, Mike's wealth of experience within the veterinary pharmaceuticals sector will provide Dechra with the commercial knowledge needed to establish, develop and drive our North American business."*

Mike Eldred, President, Dechra Veterinary Products added:

*"I am looking forward to working with the Dechra team and developing the Group's US based operations. Having gained considerable animal health sector experience during my career, I believe that I have the commercial leadership combined with the required skills in sales, strategic marketing and licensing which will be fundamental to the success of the operation going forward."*

### Enquiries:

Ian Page, Chief Executive  
Simon Evans, Group Finance Director  
**Dechra® Pharmaceuticals PLC**  
Telephone: 01782 771100

Fiona Tooley, Director  
Katie Dale, Account Manager  
**Citigate Dewe Rogerson**  
Telephone: 0121 455 8370

Mike Eldred, President  
**Dechra Veterinary Products**  
[mike.eldred@dechra.com](mailto:mike.eldred@dechra.com)  
[www.dechra.com](http://www.dechra.com)

### Notes to Editors:

In May 2003, Dechra signed a sub-license agreement with Bioenvision Inc. ("Bioenvision") for the Intellectual Property to the chemical compound, Trilostane. Under the agreement, Dechra was granted exclusive rights to the intellectual property in Trilostane in respect of animal health applications, including the veterinary development and marketing of Trilostane rights for veterinary drug applications in the USA and Canada.

Trilostane is the active ingredient in Vetoryl® the veterinary drug which has been successfully developed and marketed in the UK by Dechra's subsidiary, Arnolds Veterinary Products ("Arnolds"). The chemical entity has been highly effective in the treatment of Cushing's syndrome, an endocrine disorder in dogs, where since its launch in October 2001 in the UK, annualized sales have exceeded US\$2.5 million. This agreement with Bioenvision enables Dechra to introduce its Vetoryl product into the substantial North American market.